| Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. We show 47 historical shares outstanding datapoints in our coverage of MYGN's shares outstanding history.|
Understanding the changing numbers of MYGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MYGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MYGN by allowing them to research MYGN shares outstanding history
as well as any other stock in our coverage universe.